D'Argento E - Search Results

1

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.

Ferrara MG, Di Noia V, D'Argento E, Vita E, Damiano P, Cannella A, Ribelli M, Pilotto S, Milella M, Tortora G, Bria E. Ferrara MG, et al. Cancers (Basel). 2020 May 8;12(5):1196. doi: 10.3390/cancers12051196. Cancers (Basel). 2020. PMID: 32397295 Free PMC article. Review.

2

Are TKIs favourable for the elderly with non-small-cell lung cancer?

Rossi S, D'Argento E, Schinzari G, Dadduzio V, Di Noia V, Cassano A, Barone C. Rossi S, et al. Oncotarget. 2016 Jul 26;7(30):46871-46877. doi: 10.18632/oncotarget.9389. Oncotarget. 2016. PMID: 27206674 Free PMC article.

3

State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer.

Inno A, Di Noia V, D'Argento E, Modena A, Gori S. Inno A, et al. Transl Lung Cancer Res. 2016 Dec;5(6):599-609. doi: 10.21037/tlcr.2016.11.01. Transl Lung Cancer Res. 2016. PMID: 28149755 Free PMC article. Review.

4

Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.

Corallo S, D'Argento E, Strippoli A, Basso M, Monterisi S, Rossi S, Cassano A, Barone CM. Corallo S, et al. Target Oncol. 2017 Apr;12(2):153-161. doi: 10.1007/s11523-017-0479-4. Target Oncol. 2017. PMID: 28188446 Review.

5

DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer.

Di Noia V, Basso M, Marsico V, Cerchiaro E, Rossi S, D'Argento E, Strippoli A, Schinzari G, Iezzi R, Cassano A, Barone C. Di Noia V, et al. Future Oncol. 2019 Jul;15(20):2349-2360. doi: 10.2217/fon-2017-0025. Epub 2017 Apr 25. Future Oncol. 2019. PMID: 28440086 Clinical Trial.

6

Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?

Rossi S, Di Noia V, Tonetti L, Strippoli A, Basso M, Schinzari G, Cassano A, Leone A, Barone C, D'Argento E. Rossi S, et al. Future Oncol. 2018 Apr;14(10):919-926. doi: 10.2217/fon-2017-0499. Epub 2018 Mar 12. Future Oncol. 2018. PMID: 29528255

7

Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis.

Inno A, Di Noia V, Martini M, D'Argento E, Di Salvatore M, Arena V, Schinzari G, Orlandi A, Larocca LM, Cassano A, Barone C. Inno A, et al. Pathol Oncol Res. 2019 Apr;25(2):513-520. doi: 10.1007/s12253-018-0404-x. Epub 2018 Mar 20. Pathol Oncol Res. 2019. PMID: 29557085 Free article.

8

The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the 'unexplainable'.

Basso M, Dadduzio V, Rossi S, D'Argento E, Strippoli A, Di Salvatore M, Orlandi A, Zurlo V, Di Noia V, Barone C. Basso M, et al. Per Med. 2018 Jul 1;15(4):319-327. doi: 10.2217/pme-2017-0082. Epub 2018 Jun 21. Per Med. 2018. PMID: 29927360

9

Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies.

di Noia V, D'Argento E, Pilotto S, Grizzi G, Caccese M, Iacovelli R, Tortora G, Bria E. di Noia V, et al. Expert Opin Biol Ther. 2018 Sep;18(9):937-945. doi: 10.1080/14712598.2018.1508445. Epub 2018 Aug 9. Expert Opin Biol Ther. 2018. PMID: 30075697 Review.

10

Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations.

Magnini D, Fuso L, Varone F, D'Argento E, Martini M, Pecoriello A, Di Noia V, Arciuolo D, Fadda G, Rindi G, Richeldi L. Magnini D, et al. Mol Diagn Ther. 2018 Dec;22(6):723-728. doi: 10.1007/s40291-018-0359-3. Mol Diagn Ther. 2018. PMID: 30276554

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters